Compounds > sr141716
Page last updated: 2024-08-26

sr141716 and Coronary Disease

sr141716 has been researched along with Coronary Disease in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vinik, AI1
Blackburn, GL; Waltman, BA1
Forrester, JS; Shah, PK1

Reviews

3 review(s) available for sr141716 and Coronary Disease

ArticleYear
The metabolic basis of atherogenic dyslipidemia.
    Clinical cornerstone, 2005, Volume: 7, Issue:2-3

    Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Drugs, Investigational; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Pioglitazone; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Thiazolidinediones

2005
Pharmacotherapy to reduce visceral fat.
    Clinical cornerstone, 2005, Volume: 7, Issue:2-3

    Topics: Anti-Obesity Agents; Coronary Disease; Cyclobutanes; Exercise; Feeding Behavior; Humans; Intra-Abdominal Fat; Lactones; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant

2005
Emerging strategies for increasing high-density lipoprotein.
    The American journal of cardiology, 2006, Dec-01, Volume: 98, Issue:11

    Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Cannabinoid Receptor Antagonists; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Humans; Lipoproteins, HDL; Peroxisome Proliferator-Activated Receptors; Piperidines; Pyrazoles; Rimonabant; Risk Factors

2006